PRRT2 and Thromboembolism: Herein, we propose a novel inhibitory pathway of NF-κB-mediated PLCγ2-PKC activation by auraptene in human platelets, and further supported that auraptene possesses potent activity for clinical therapeutic or prophylactic application for treatment with thromboembolic diseases.